Lovaltech Overview
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Early Stage VC
- (In Progress)
- Latest Deal Amount
-
$469K
- Investors
-
5
Lovaltech General Information
Description
Developer of an intranasal vaccine platform designed to prevent and reduce the transmission of respiratory infectious diseases through mucosal immunity. The company offers a muco-excipient platform combining recombinant antigens with nanocarrier-based delivery technology and supports proteins, mRNA, peptides, and viral vectors, enabling pharmaceutical companies and healthcare organizations to develop needle-free vaccines and enhance localised immune protection against infectious diseases.
Contact Information
Website
www.lovaltechnology.comCorporate Office
- 49 Boulevard Preuilly
- 37000 Tours
- France
Corporate Office
- 49 Boulevard Preuilly
- 37000 Tours
- France
Lovaltech Timeline
Lovaltech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Early Stage VC | 01-Jan-2026 | $469K | In Progress | Clinical Trials - Phase 2 | ||
| 8. Equity Crowdfunding | 01-Mar-2026 | Announced | Clinical Trials - Phase 2 | |||
| 7. Debt - General | Announced | Clinical Trials - Phase 1 | ||||
| 6. Grant | Completed | Clinical Trials - Phase 1 | ||||
| 5. Grant | 31-Aug-2025 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC | 01-Jun-2025 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 23-Apr-2024 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 31-May-2023 | $1.63M | $1.63M | Completed | Pre-Clinical Trials | |
| 1. Accelerator/Incubator | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Lovaltech Signals
Lovaltech Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bpi (Boise) | Venture Capital | Minority | ||
| UI Investissement | PE/Buyout | Minority | ||
| Bpifrance | Sovereign Wealth Fund | Minority | ||
| Da Vinci Labs | Accelerator/Incubator | Minority | ||
| The Place by CCI 37 | Accelerator/Incubator |
Lovaltech FAQs
-
Where is Lovaltech headquartered?
Lovaltech is headquartered in Tours, France.
-
What is the size of Lovaltech?
Lovaltech has 6 total employees.
-
What industry is Lovaltech in?
Lovaltech’s primary industry is Biotechnology.
-
Is Lovaltech a private or public company?
Lovaltech is a Private company.
-
What is Lovaltech’s current revenue?
The current revenue for Lovaltech is .
-
How much funding has Lovaltech raised over time?
Lovaltech has raised $9.8M.
-
Who are Lovaltech’s investors?
Bpi (Boise), UI Investissement, Bpifrance, Da Vinci Labs, and The Place by CCI 37 have invested in Lovaltech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process